Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed/refractory acute lymphoblastic leukemia

Gang Heng1*, Jiankun Jia1*, Shiqi Li1, Gang Fu2, Meiling Wang1, Dabing Qin2, Yunyan Li1, Li Pei2, Xiaobo Tian2, Jiasi Zhang2, Yi Wu3, Shali Xiang2, Jia Wan2, Wei Zhu1, Pei Zhang2, Qianzhen Zhang1, Xi Peng2, Linling Wang1, Ping Wang2, Zhihao Wei1, Yingzi Zhang1, Guiqin Wang1, Xue Chen2, Chengcheng Zhang1, Yanni Sun2, Wenxu Zhao1, Yahan Fan4, Zhi Yang1, Jieping Chen2, Cheng Qian1,5

* These authors contributed equally to this work

1 Center of Biological Therapy, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China;

2 Center of Haematology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China;

3 Department of Nephrology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China;

4 Department of Blood Transfusion, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China

5 Center for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, China
Correspondence to:

Prof. Cheng Qian, Center of Biological Therapy, Southwest Hospital, Third Military Medical University (Army Medical University), and Center for Precision Medicine of Cancer, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China. Tel: 86-23-68765957; Fax: 86-23-68752247; E-mail: cqian8634@gmail.com

Or Prof. Jieping Chen, E-mail: chenjpxn@163.com, or Dr. Zhi Yang, E-mail: yz2003can@126.com

Running Title: Sustained efficacy of humanized anti-CD19 CAR-T cells

Key Words: Humanized CAR-T, long-term persistence, plasma exchange

Acknowledgments

This work was supported by National Key Research and Development Program (2016YFC1303405), National Natural Science Foundation of China (81520108025), Chongqing Precision Biotech Co., Ltd (JSXM-1).

The authors declare no potential conflicts of interest.
Translational Relevance

CAR-T against CD19 has shown significant anti-tumor activity in relapsed/refractory acute lymphoblastic leukemia (r/r ALL). However, relapse still remains the major concern of anti-CD19 CAR-T cell therapy. One mechanism for relapse is the development of humoral and/or cellular immune responses against some specific epitopes of scFv in the CAR structure, which are derived from a murine antibody. In this investigator-initiated trial, we developed a humanized anti-CD19 scFv CAR-T (hCAR-T) cells and infused these cells to patients with r/r ALL. Sustained B cell aplasia and long-term persistence of hCAR-T cells were observed in these patients. Moreover, four patients with high tumor burden and rapidly progressive disease experienced grade 3-4 of cytokine release syndrome (CRS). These severe CRSs were successfully controlled by tocilizumab, glucocorticoid and plasma exchange (PE). Our data provide a potential method to reduce the relapse rate for patients accepting CAR-T cell therapy.
Abstract

Purpose: Immunogenicity derived from the murine scFv, a major molecular component of chimeric antigen receptors (CARs), may limit the persistence of CAR-T cells, resulting in tumor relapse of complete remission (CR) patients. In this study, we developed a humanized anti-CD19 scFv CAR-T (hCAR-T) to treat patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

Experimental design: In this one-arm, open-labeled study, we infused the T cells modified with hCAR to patients with r/r ALL. Patients were evaluated with long-term follow-up for response and safety of the treatment. The study was registered at Clinicaltrials.gov (NCT02349698).

Results: Ten patients with r/r ALL were recruited for this study. All were response evaluable and all achieved CR; eight patients remained CR, and six were in CR for over 18 months without further treatment. A long-term persistence of hCAR-T cells was observed in most of the patients. Among these patients, four of them with high tumor burden and rapidly progressive disease (median 58%) experienced grade 3-4 CRS and neurotoxicity. These severe CRSs were successfully controlled by tocilizumab, glucocorticoid and plasma exchange (PE).

Conclusions: T cells expressing the humanized anti-CD19 scFv CAR exhibited sustained therapeutic efficacy in the treatment of r/r ALL. Low replase rate was associated with the long-term persistence of CAR-T cells.
Introduction

Chimeric antigen receptors (CARs) are genetically modified receptors that couple a single-chain Fv (scFv) domain to intracellular cell signaling domains of the T cell receptor. T cells engineered to express these receptors have shown significant therapeutic efficacy in treating relapsed/refractory acute lymphoblastic leukemia (r/r ALL) with complete remission (CR) rates reaching 80–90% at first month, 65–75% at six months and 40–50% at 12 months (1-5). However, relapse still remains the major concern of CD19 CAR-T cell therapy.

One of the causes of relapse is CD19-negative B-ALL progression (6); Maude et al. (1, 2) and Lee et al. (4) report that this was the case in approximately 10–30% of relapsed patients. Another common cause is the loss of CAR-T cells, leading to CD19-positive ALL regression. Multiple mechanisms may be responsible for the inability of CAR-T cells to persist in vivo. One such mechanism is the development of humoral and/or cellular immune responses against some specific epitopes of the scFv in the CAR structure, which is derived from a murine antibody (7-12). Besides this, as reported by others, patients with a high and rapidly progressive tumor burden are at high risk for severe adverse events and early relapse after accepting CAR-T cell therapy (5, 13).

In this study, we developed an optimal humanized anti-CD19 CAR structure derived from FMC63 to reduce the immunogenicity of CAR. Ten patients with r/r ALL were treated with humanized anti-CD19 CAR-T (hCAR-T) cells to evaluate its
efficacy and safety. Our data showed that long-term sustained therapeutic efficacy could be achieved. CRS and neurotoxicity in patients with a high tumor burden and rapidly progressive disease could be controlled by tocilizumab, glucocorticoid and plasma exchange (PE).
Materials and Methods

Study design

This clinical trial was an investigator-initiated trial for the treatment of CD19+ r/r ALL and was approved by the institutional review board (IRB) of the Southwest Hospital of Third Military Medical University (Chongqing, China) and all patients signed informed consents. The study was registered at Clinicaltrials.gov (NCT02349698) and performed according to the principles of the Declaration of Helsinki. All patients or their guardians provided written informed consent before they were recruited into this study.

All patients participating in this study volunteered and had been diagnosed with B-ALL through clinical manifestations and the bone marrow examination. All the enrolled patients had relapsed or refractory disease. In this study, CR was defined as less than 5% marrow blasts and absence of circulating blasts, and no extramedullary sites of disease, regardless of cell count discovery. Ten patients with ALL were enrolled, including three females and seven males and the median age was 16 years. Further patient information is presented in table 1.

Eight patients received a FC (fludarabine 25 mg/m², cyclophosphamide 900 mg/m²) preconditioning treatment, except for patients P3 and P4, who were offered and accepted Hyper-CVAD-A (cyclophosphamide 300 mg/(m²/12h), vincristine 2 mg/day, epirubicin 30 mg/day, dexamethasone 20 mg/day) preconditioning treatment because of an extremely high tumor burden. Day at infusion was defined as day 0. The
hCAR-T cells were administered by intravenous infusion in two split-dose manners, during which either 10%, 30% and 60%, or 40% and 60%, of the total cells were infused on continuous days. The patients were followed by disease assessment via bone marrow and peripheral blood every month for the first two months, every two months from months 3 to 6 and every 3 months afterward. Adverse events, including neurotoxicity, were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, and are listed in Supplementary Table S1. CRS was graded according to MSKCC CRS grading system. Severe CRS was defined as ≥grade 3.

The generation of hCAR-T cells

Lentivirus was produced and purified from the supernatant of HEK293T cell cultures with transfection of a pCDH plasmid vector consisting of the humanized anti-CD19 scFv (only containing 25% of murine sequence), CD8 hinge, CD8 transmembrane domain, CD137 costimulatory signal and CD3 zeta intracellular domains. Peripheral blood mononuclear cells (PBMCs) were isolated and activated by anti-CD3/CD28 paramagnetic beads followed by lentivector transduction and expansion in vitro with IL-7 and IL-21 for approximately 10–14 days to generate hCAR-T cells. Phenotypes of hCAR-T cells were analyzed before administration. A representative image is presented in Supplementary Fig. 1. The materials and methods of flow cytometry (FCM) are provided in Supplementary data.

Quantitative PCR for detection of DNA copies
Blood samples were obtained following the trial procedure. Genomic DNA was extracted from the blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Duesseldorf, Germany, 51106) according to the provided protocol. We applied TaqMan probes for real-time quantitative polymerase chain reaction (qPCR) in an ABI QuantStudio 5 (Applied Biosystems, Foster City, CA, USA). Taqman primers used were 50-CTTCCCGTATGGCTTTCATTTTCTC-30 (Forward) and 50 CGCCACGTTGCCTGACA-30 (Reverse). The probe was 50-FAM-ACGGGCCACAACTCCT-30. The TaqMan method was performed in accordance with the published protocol (14). CDKN1A was used as the control and produced a correction factor for DNA copy number. Healthy donor DNA was used as a negative control and to define the pre-infusion acceptance ranges of the qPCR method. The lower limit of quantification (LLOQ) was determined as 1 copy/ng genomic DNA.

**Cytokine detection**

Plasma samples were stored at -80°C and were analyzed in batches using a customized kit containing a 15-plex human cytokine magnetic bead panel (Milliplex, Darmstadt, Germany, SPR372) with the MAGPIX instrument (Luminex, Austin, TX, USA). The plasma levels of cytokines IL-2, IL-6, IL-10, FLT3LG, Fractalkine, GM-CSF, IFN-γ, TNF-α, IL-1α, IP-10, MCP-1, MIP-1α and MIP-1β were measured in the experiment. Samples were undiluted, and each was assayed in duplicate. Data analysis was conducted following the related protocol and algorithm using MILLIPLEX® Analyst 5.1 software.
Human anti-mouse antibody detection

Cryopreserved serum samples of patients treated with hCAR-T cells or murine-derived CAR-T cells (these patients had been registered in a previous study (15) and all achieved CR) were measured for human anti-mouse antibodies (HAMA) using an ELISA assay (LEGEND MAX™ Human Anti-Mouse Ig (HAMA) ELISA Kit; Biolegend (San Diego, California, USA), 438308) specific for human immunoglobulin G (IgG), according to the kit instructions.

Statistical analysis

All statistics were analyzed in GraphPad Prism 7. Descriptive statistics (median/range, percentage) were reported for variables. Comparison of cytokines in the two groups was performed using the Mann–Whitney test. Statistical significance was defined as P<0.05. For analysis of leukemia-free survival (LFS), an event was defined as relapse. Death was the event for analysis of overall survival (OS). LFS and OS were determined by the Kaplan–Meier method.
Results

Characteristics of patients and hCAR-T cells

From June 2017, ten patients, aged from 5 to 40 years old, with r/r ALL were enrolled in this study. All the patients had received 5 to 13 intensive therapies including chemotherapy regimens; 2 of them had undergone HSCT before hCAR-T cell infusion. The proportion of marrow blasts ranged from 0.7% to 90%, median 4.5%, and minimal residual disease (MRD) was detected positively in ten patients by flow cytometry and/or ALL fusion gene detection (Table 1). Among these patients, three (patients 2, 7 and 9) had central nervous system leukemia (CNSL) and accepted intrathecal chemotherapeutic drugs injection regularly to relieve symptoms such as dizziness and headache.

The hCAR-T cell dose levels ranged from $2.3 \times 10^5$ cells/kg to $4.17 \times 10^7$ cells/kg, median $2.47 \times 10^6$ cells/kg (Table 1). The manufacturing procedure is shown in Fig. 1A. After cultivation, the phenotype of hCAR-T cell products was detected, including naïve T cells (Tn), central memory T cells (Tcm), effector memory T cells (Tem), and effector T cells (Teff) (Fig. 1B and Supplementary Fig. 1). Inhibitory markers such as PD-1, Tim-3 and Lag-3 on the T cells were also checked (Fig. 1C). The median ratio of CD4$^+$ and CD8$^+$ T cells was 0.70 (range, 0.17 to 4.6) and 0.68 (range, 0.17 to 2.33) in CAR$^+$ and CAR$^-$ T cells, respectively (Fig. 1D).

Treatment with hCAR-T cells achieved long-term complete remission

On day $28 \pm 7$ after hCAR-T cell infusion, the clinical responses were evaluated in
the ten patients. All were response-evaluable and achieved morphologic CR initially, and the CR rate was 100% (Fig. 2A). Detection of MRD by multi-parametric FCM and PCR was negative in all ten patients. Three patients with CNSL had no detectable cerebral diseases. During the follow-up period, one patient (P3) experienced CD19 positive relapse at 6 months after infusion; and two patients (P4 and P10) proceeded to HSCT at 4 months and 3 months, respectively, after infusion. Patient 4 had a CD19− relapse at 12 months, and P10 remained CR.

Both the overall survival (OS) and leukemia-free survival (LFS) rate were 100% at 3 months. And the OS and LFS rate were 100% and 90% at 6 months, respectively (Figs. 2B, C). Long-term remissions (>12 months) were observed in seven patients (P1, P2, P5, P6, P7, P8 and P9). Among those patients, six have remained sustained leukemia-free survival for over 18 months, and two patients have maintained disease-free survival for 2 years. Another patient (P10) has been in remission for 8 months. In the peripheral blood and bone marrow of these patients, B cell aplasia was observed (Figs. 2D and E).

**Long-term persistence of hCAR-T cells was observed in these patients**

Dynamic changes of CD19+ cells in the peripheral lymphocytes and bone marrow were shown in the Fig. 3. DNA copies of hCAR-T cells were also detected after infusion. In most patients, the DNA copy numbers had a rapid increase in first 2 weeks after infusion but declined quickly during the next few weeks (Figs. 2F and G). However, in some patients (P2, P4, P5, P8 and P9), the DNA copies of hCAR-T cells experienced several rounds of fluctuation during the follow-up time.
Meanwhile, we observed the re-appearance of CD19+ cells in PB or BM (Figs. 3B, D, E, H and I). For example, the DNA copy number dramatically increased to 319881 copies/μg after 520 days of infusion along with a sharp decrease of CD19+ cells in bone marrow of patient 2 (Fig. 3B). On the other hand, DNA copies in patient 6 declined relatively slower than other patients and remained a high level for more than 12 months, while consistent CD19+ cells aplasia was observed in PB or BM (Fig. 3F).

Furthermore, for each patient who had a recovery of CD19+ cells during the follow-up period, we conducted multi-parametric FCM tests to verify whether these cells were normal or malignant B cells. For patients P8 and P9 who had a recovery of CD19+ cells at the last follow-up, we did multi-parametric FCM tests to analyze these immature cells and found that they were early pre-B cells and pre-B cells without any sign of malignance (Supplementary Fig.2). The E2A-PBX1 gene (positive for P8 when enrolled) and BCR-ABL gene (positive for P9 when enrolled) were also negative for patients P8 and P9 at the last follow-up (Supplementary Fig. 3).

**Low level of HAMA was detected in serum of patients infused with hCAR-T cells**

Cryopreserved serum samples were analyzed for human IgGs specific for mouse proteins by ELISA. Results are shown in Supplementary Fig. 4A. For eight patients (except for patients P6 and P9), minimally positive IgG HAMA before infusion was detected and which had a significant increase after infusion. The peak level of HAMA was detected in the first 3 weeks post-infusion among most patients. For patients P1 and P5, the HAMA peaked at about 3 months after infusion. After that, the HAMA
quickly decreased to the undetected level until the latest follow-up. For comparison, we also detected the level of HAMA in another five patients (labeled patients a-e) who had accepted mouse-derived CAR-T cells (FMC63) and achieved CR, as described in our previous article (15). Similarly, a baseline level of HAMA was detected in four patients. However, the dynamic change of HAMA seemed to be irregular but was always detectable during the follow-up (Supplementary Fig.4B).

**Rapidly ascending number of hCAR-T cells in peripheral blood was a sign of recovery from systemic toxicity responses**

Fig. 4 shows the kinetics of DNA copies of hCAR-T and IL-6 from 1 to 2 weeks after infusion. During the first 5–6 days after infusion, the DNA copies of hCAR-T cells in peripheral blood remained at the low level, but some inflammatory cytokines, including IL-6, dramatically increased and the systemic toxicities were apparent or severe in this period. Approximately 7–9 days after infusion, DNA copies in peripheral blood had a rapid rise and arrived at a maximum one or two days later. At the same time, the serum level of IL-6 decreased dramatically and temperature also returned to the normal value. Systemic toxicities also turned to the endpoint and the damaged function of organs recovered gradually. This appeared to be due to the fact that the majority of CD19+ leukemic cells existed in the bone marrow, and the primary and most intense anti-tumor responses had occurred in that stage. Once leukemic cells were eradicated completely, hCAR-T cell responses would be attenuated, resulting in decline of cytokine production and inflammatory responses.
The incidence of CRS and neurotoxicity

CAR-T cells can induce a clinical syndrome of fevers, hypotension and hypoxia associated with marked elevations of serum cytokines in some patients. This syndrome has been termed cytokine release syndrome (CRS) (16, 17). To analyze the severity of CRS clearly, patients in our study were divided into two groups according to the CRS grade. Four patients with grade 3–4 CRS were defined as the first group, whereas the other six patients with grade 1–2 CRS were defined as the second group. The temperature of each patient was recorded every 1–4 hours during the treatment (Supplementary Figs. 5A, B). Compared with patients who had grade 1-2 CRS, patients who had grade 3–4 CRS experienced fever earlier after hCAR-T cell infusion and the fever reached a higher maximum temperature (P<0.05) and was of longer duration (Supplementary Fig.6A). We also measured the levels of IL-6, CRP, and IFN-γ regularly in all patients to help diagnose and treat CRS (Supplementary Figs. 5C-H). We found that IL-6 in patients with grade 3–4 CRS increased much more rapidly (P<0.05), and the peak levels of these cytokines were distinctly higher than those of patients with grade 1–2 CRS (P<0.01) (Supplementary Fig. 6). The four patients with grade 3–4 CRS also developed grade 1–4 neurotoxicity. P3 and P4 developed multiple neurological symptoms after CAR-T cell infusion, including headache, nausea, vomiting and epilepsy. Typically, neurotoxicity presented at the time point when the patients began to recover from the CRS. This was likely partly due to the long-term disruption to the blood–brain barrier from the inflammatory cytokines such as IL-6 (18). The details of adverse events are listed in Supplementary
Currently, temperature and IL-6 are the two most used factors to diagnose CRS. In this study, we found that those patients who experienced grade ≥3 CRS also exhibited a higher concentration of interferon-γ (IFN-γ), interleukin-10 (IL-10), fractalkine, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Supplementary Fig. 6). This finding suggested that one or more of these cytokines could be used as clinically diagnostic biomarkers for grade ≥3 CRS, which was consistent with the results reported by David T. Teachey et al (19).

Management of patients with severe CRS

For 4 patients with grade 3–4 CRS, the tumor loads in their bone marrow were extremely high and rapidly progressive. As shown in Supplementary Fig.7, all of these patients had received 6 to 11 rounds of chemotherapy previously. Although 3 patients had ever achieved CR after chemotherapy, the remission time was obviously short and they would become resistant to these regimens once the relapse occurred. Even worse, patient 4, whose tumor disease increased to 95% after lymphodepletion, had never achieved CR during the entire period of chemotherapy (Supplementary Fig. 7B). For patients P3 and P4, considering that the tumor load in their bone marrow was extremely high (≥90%) and the CRS would become uncontrollable, a more intensive preconditioning regimen Hyper-CVAD-A instead
of FC was conducted in these 2 patients (Supplementary Figs. 7A, B).

For management of grade 3-4 CRS, early use of tocilizumab and glucocorticoid is recommended (20-22). After infusion of CAR-T cells, the temperature responded rapidly to this therapy, and ibuprofen was used to further control the temperature. At the same time, tocilizumab and glucocorticoid were administrated to these patients even though elevated cytokines were not observed. In addition to receiving tocilizumab and glucocorticoid, patients P3 and P4 also received mannitol to control cerebral edema of neurotoxicity (Fig. 5 and Supplementary Fig. 8).

Along with tocilizumab or glucocorticoid, for patients P6 and P10, plasma exchange (PE) was administered to reduce the serum level of inflammatory cytokines. For patient P6, PE was conducted on days 6 and 7 (Fig. 5C). A total of 1800 ml of plasma was exchanged, with the IL-6 reducing from 37510 pg/ml to 375.9 pg/ml within 24 hours, and other symptoms like fever were quickly relieved. For P10, PE was administrated on day 8, and 750 ml of plasma was exchanged (Fig. 5D). After PE, his serum IL-6 level had an evident decrease from 2656 pg/ml to 499.5 pg/ml, accompanied with significant relief of other symptoms, indicating that PE might be an effective method in the management of CRS.
Discussion

Chimeric antigen receptor T (CAR-T) cell therapy has shown substantial clinical efficacy in treating B-lineage malignancies, particularly in relapsed/refractory acute lymphoblastic leukemia (ALL), where a 70–90% CR rate has been achieved in the first month after infusion. Despite the inspiring initial achievement, relapse remains a major challenge in some patients with the recovery of CD19+ leukemia cells due to the loss of the CAR-T cells. There are many factors contributing to early loss of the CAR-T cells, including the CAR structure itself, cultivation methods of CAR-T cells and the immunogenicity of CAR.

In this study, we focus on the immunogenicity of the CAR structure because most of the scFvs of CAR are derived from murine antibodies, which may develop an immune response specific for epitopes in murine scFvs and reduce the persistence of CAR-T cells. To reduce the immunogenicity of CAR, we developed a humanized anti-CD19 scFv and found that it shows similar anti-leukemia efficacy in preclinical study, providing the basis for its clinical use.

To evaluate the efficacy and safety of anti-CD19 hCAR-T cells, we analyzed data from ten patients with a diagnosis of r/r ALL. Among them, all patients were response evaluable, and all achieved morphologic CR (100%) and MRD-negative CR (100%). With long-term follow-up, we observed that both the overall survival (OS) and leukemia-free survival (LFS) rate were 100% at 3 months. And the OS and LFS rate were 100% and 90% at 6 months, respectively. Previous study
showed that treatment of r/r ALL with Tisagenlecleucel, FDA-approved CAR-T based on murine scFv, resulted in the overall remission rate at 81% within 3 months. The rates of overall survival and event-free survival were 90% and 73% at 6 months, respectively (2). In our study, the long-term persistence of hCAR-T cells has been observed in six patients with more than 1000 DNA copies/μg of CAR-T cells detected in peripheral blood at or after 6 months.

Relapse remains a major challenge for CAR-T cell therapy. In this study, we found that hCAR-T treatment resulted in eight out of ten patients remaining CR until now and six in CR for over 18 months without further treatment. Only two relapses have been observed—in patients P3 and P4 during the follow-up. For P3, hCAR-T cells were lost at 4 months and leukemia cells with CD19 positive were found at 5.7 months. For P4, early loss of hCAR-T cells was also observed at 64 days after infusion with detection of less than 100 DNA copies/μg in peripheral blood. However, the DNA copies in P4 experienced a 5-fold increase after the recovery of CD19+ cells at 83 days, and then CD19+ cells in the peripheral blood and in the bone marrow descended to a level lower than 1%. 4 months after infusion, patient P4 proceeded to accept HSCT and had a CD19− relapse at 12 months after infusion. Considering the reasons for the early loss of hCAR-T cells in these 2 patients, the most probable one is that these 2 patients were in a high disease burden and the ratio of CAR-T cells to target CD19+ leukemia cells was lower than those with a low disease burden, potentially resulting in the early exhaustion of CAR-T cells (5). Another reason may be that high-dose glucocorticoids have been used in these two patients because both
of them had developed grade 3-4 CRS. Glucocorticoid is immunosuppressive and has been reported to negatively affect the survival of CAR-T cells (17, 23). These two patients were also treated with preconditioning regimen Hyper-CVAD-A instead of FC before CAR-T infusion, and it was reported that incorporation of fludarabine into the lymphodepletion regimen was associated with superior CAR-T cell expansion and persistence and a lower risk of CD19-positive relapse (8, 24).

Management of toxicity is also an important part of the clinical application for CAR-T cell therapy (25). As reported, the most common adverse events observed were CRS and neurotoxicity (5, 23). Recently, there have been some studies on the pathological and kinetic mechanism of CAR-T–related toxicity (21, 26). Despite significant progress, there are still no good solutions for reducing the risk of CAR-T related toxicity, particularly for those with a bulk and rapid progressive tumor disease (5, 27). In this study, we found that early use of tocilizumab and glucocorticoid before cytokines elevations were effective for the treatment of severe CRS. Although the early use of tocilizumab and glucocorticoid could not reduce the secretion of cytokines such as IL-6, this method could alleviate the inflammatory responses in the body and reverse the organ toxicities. Besides this effect, glucocorticoid could also reduce local inflammatory reactions in the brain, potentially helping to alleviate some neurotoxic symptoms.

Furthermore, in our study, we utilized PE to manage severe CRS. PE has been commonly used in the treatment of a variety of hematological, neurological, nephrological and rheumatological disorders (28-30) but has only been reported to
be applied for the management of CRS in a recent case report by Xia Xiao et al. (31). The therapeutic effect of PE was likely achieved through the removal of pathogenic substances; thus we speculated that PE could be used to control CRS by removing inflammatory factors. In the study, PE was first used to take control of life-threatening CRS in P6. The levels of IL-6 and other inflammatory cytokines dramatically decreased, and other symptoms, including the fever and dyspnea, were quickly relieved. According to this successful practice, we conducted PE once again in P10 who was at high risk for grade ≥3 CRS because his tumor burden increased significantly from 3% to 63% after pre-conditioning therapy. After PE, his serum IL-6 level had an evident decrease from 2656 pg/ml to 499.5 pg/ml. These results indicated PE was feasible and could be included in the management of grade ≥3 CRS.

Taken together, we demonstrated that T cells expressing the humanized anti-CD19 scFv CAR exhibited sustained therapeutic efficacy and low relapse in the treatment of r/r ALL. Low relapse rate was associated with the long-term persistence of CAR-T cells in the treated patients.
Authors' Contributions

Cheng Qian, Jieping Chen and Zhi Yang designed the research study. Gang Heng, Jiankun Jia, Shiqi Li, Gang Fu, Jiasi Zhang, Li Pei, Dabing Qin, Xiaobo Tian, Jia Wan, Yingzi Zhang, Pei Zhang, Ping Wang, Xi Peng, Shali Xiang and Xue Chen performed the research. Meiling Wang and Yanni Sun conducted the flow cytometry tests. Yunyan Li and Linling Wang cultivated CAR-T cells. Wei Zhu performed the PCR to detect CAR-T DNA copies. Wenxu Zhao, Chengcheng Zhang, Zhihao Wei and Guiqin Wang performed preclinical study of humanized scFv. Yi wu and Yahan Fan conducted the plasma exchange for patient P6 and P10. Qianzhen Zhang conducted the ELISA assay for HAMA. Gang Heng and Jiankun Jia wrote the paper.
References:


Figure legends:

Fig. 1: Manufacturing procedure and characteristics of hCAR-T cells before infusion. (A) Manufacturing procedure for hCAR-T cells. (B) Percentage of Tn, Tcm, Tem and Teff cells in hCAR-T products. (C) Percentage of PD-1, Tim-3 and Lag-3 in hCAR-T products. (D) Ratio of CD4+ and CD8+ cells in CAR+ and CAR− T cells. PD-1: programmed cell death protein 1, Tim-3: T-cell immunoglobulin and mucin-domain containing-3, Lag-3: Lymphocyte-activation gene 3.

Fig. 2: Clinical responses of ten r/r ALL patients. (A) Clinical outcomes of the ten patients. Overall survival (OS) rate (B) and leukemia-free survival (LFS) rate (C) of the ten patients. The OS and LFS rates at 3 and 6 months were calculated. (D–E) Percentage of CD19+ cells of nucleated cells in the peripheral blood and bone marrow, respectively. Negative results were defined as less than 3% of CD19+ B cells in peripheral blood and bone marrow. (F) Percentage of hCAR+ T cells in the peripheral lymphocytes was detected by FCM. (G) DNA copies of hCAR-T were detected by qPCR in the peripheral blood. A positive result was defined as more than 3% of CAR-T cell in peripheral lymphocytes and more than 1000 hCAR-T DNA copies per microgram genomic DNA.

Fig. 3: Detection of DNA copies of hCAR-T and CD19+ cells in peripheral blood and bone marrow during follow-up. (A–I) Dynamics of DNA copies and CD19+ cells in the ten patients. The percentage of CD19+ cells was calculated among lymphocytes in
PB or BM nucleated cells. Except for P3, who had a relapse of CD19+ malignant B cells, the other patients’ recurrent CD19+ B cells were verified as normal B cells by 12-parametric FCM. The DNA copy number of CAR-T cells was detected using quantitative PCR. PB: peripheral blood, BM: bone marrow, R: relapse.

Fig. 4: The rapidly ascending number of hCAR-T cells accompanied a decrease of IL-6 in the peripheral blood. (A–K) Kinetics of IL-6 and DNA copies in peripheral blood of the ten patients. After the sharp increase of CAR-T DNA copies in the peripheral blood, inflammatory cytokines such as IL-6 rapidly decline and organ functions began to recover from CRS.

Fig. 5: Management details for CRS in four patients with grade 3–4 CRS. (A–D) Kinetics of WBC and IL-6 in PB of four patients of high tumor burden with grade ≥3 CRS are shown. Main interventions for toxicity management and analysis of cell phenotype in peripheral blood at key time points are labeled. For patients P3 and P4, Hyper-CVAD-A was chosen as the pre-conditioning regimen, whereas for patients P6 and P10, the regular FC regimen was given. Day at infusion was defined as day 0. WBC: white blood cell; PB: peripheral blood. Hyper-CVAD-A: cyclophosphamide, vincristine, epirubicin, dexamethasone; FC: fudarabine, cyclophosphamide.
<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Gene detection</th>
<th>Prior intensive therapies</th>
<th>HCT before</th>
<th>Marrow blasts before lymphodepletion</th>
<th>Marrow blasts after lymphodepletion</th>
<th>Dose level ($\times10^6$/kg)</th>
<th>CRS Grade</th>
<th>Depletion therapy</th>
<th>Initial response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>male</td>
<td>16</td>
<td>WT1/ABL</td>
<td>5</td>
<td>YES</td>
<td>13%</td>
<td>1%</td>
<td>3.74</td>
<td>2</td>
<td>FC</td>
<td>CR, MRD-</td>
</tr>
<tr>
<td>2</td>
<td>male</td>
<td>16</td>
<td>-</td>
<td>9</td>
<td>NO</td>
<td>1.2%</td>
<td>/</td>
<td>2.46</td>
<td>2</td>
<td>FC</td>
<td>CR, MRD-</td>
</tr>
<tr>
<td>3</td>
<td>female</td>
<td>8</td>
<td>GLP TEL/AML1; MLL/MLLT1</td>
<td>11</td>
<td>NO</td>
<td>90%</td>
<td>/</td>
<td>41.67</td>
<td>3</td>
<td>Hyper-CVAD-A</td>
<td>CR, MRD-</td>
</tr>
<tr>
<td>4</td>
<td>female</td>
<td>12</td>
<td>WT1</td>
<td>6</td>
<td>NO</td>
<td>90%</td>
<td>95%</td>
<td>12.3</td>
<td>4</td>
<td>Hyper-CVAD-A</td>
<td>CR, MRD-</td>
</tr>
<tr>
<td>5</td>
<td>male</td>
<td>17</td>
<td>-</td>
<td>6</td>
<td>YES</td>
<td>6%</td>
<td>/</td>
<td>2.48</td>
<td>2</td>
<td>FC</td>
<td>CR, MRD-</td>
</tr>
<tr>
<td>6</td>
<td>male</td>
<td>18</td>
<td>GLP TEL/AML1; WT1</td>
<td>7</td>
<td>NO</td>
<td>26.5%</td>
<td>69.5%</td>
<td>6.35</td>
<td>3</td>
<td>FC</td>
<td>CR, MRD-</td>
</tr>
<tr>
<td>7</td>
<td>female</td>
<td>5</td>
<td>/</td>
<td>12</td>
<td>NO</td>
<td>3%</td>
<td>10.1%</td>
<td>1.68</td>
<td>2</td>
<td>FC</td>
<td>CR, MRD-</td>
</tr>
<tr>
<td>8</td>
<td>male</td>
<td>40</td>
<td>E2A-PBX1; WT1</td>
<td>5</td>
<td>NO</td>
<td>2%</td>
<td>/</td>
<td>0.23</td>
<td>2</td>
<td>FC</td>
<td>CR, MRD-</td>
</tr>
<tr>
<td>9</td>
<td>male</td>
<td>40</td>
<td>BCR/ABL; GLPP16/9q21;WT1</td>
<td>13</td>
<td>NO</td>
<td>0.7%</td>
<td>/</td>
<td>0.5</td>
<td>2</td>
<td>FC</td>
<td>CR, MRD-</td>
</tr>
<tr>
<td>10</td>
<td>male</td>
<td>16</td>
<td>E2A-PBX1</td>
<td>5</td>
<td>NO</td>
<td>3%</td>
<td>63%</td>
<td>0.86</td>
<td>3</td>
<td>FC</td>
<td>CR, MRD-</td>
</tr>
</tbody>
</table>
The bone marrow blasts in this table are calculated based on marrow morphological tests or flow cytometry. The MRD in initial response was determined by both flow cytometry and RT-PCR.
Evaluation of patients → Autologous PBMCs → Activated by anti-CD3/CD28 paramagnetic beads → Lentiviral transduction → Expanded with IL-7 and IL-21 → CAR-T cell product

Figure 1

A

B

C

D

% PD-1 Tim-3 Lag-3

% CD4/CD8

CAR+ CAR-
Figure 2

A

B

C

D

E

F

G

Accept HSCT

Ongoing CR

Relapse CD19-

Relapse CD19+

CD19% in PB<3%

CD19% in PB>3%

R

Relapse

CAR% in PB<3%

CAR% in PB>3%

R

Relapse

CAR copies in PB>1000 copies/ug

CAR copies in PB<1000 copies/ug

R

Relapse

Months after infusion
Figure 3

(A) P1  
(B) P2  
(C) P3  
(D) P4  
(E) P5  
(F) P6  
(G) P7  
(H) P8  
(I) P9  
(J) P10

- Red line: CD19+ in PB
- Purple line: CD19+ in BM

DNA Copies

CD19+ % in PB
CD19+ % in BM

Days after infusion

Copies/ug
Figure 4
# Clinical Cancer Research

**Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed/refractory acute lymphoblastic leukemia**

Cheng Qian, Gang Heng, Jiankun Jia, et al.

*Clin Cancer Res* Published OnlineFirst November 15, 2019.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-19-1339</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2019/11/15/1078-0432.CCR-19-1339.DC1">http://clincancerres.aacrjournals.org/content/suppl/2019/11/15/1078-0432.CCR-19-1339.DC1</a></td>
</tr>
<tr>
<td>Author Manuscript</td>
<td>Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://clincancerres.aacrjournals.org/content/early/2019/11/15/1078-0432.CCR-19-1339">http://clincancerres.aacrjournals.org/content/early/2019/11/15/1078-0432.CCR-19-1339</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>